# US 2016/0354312 A1 · Formulations of jasmonates and nanocarriers or microcarriers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354312 A1
- Document ID: US20160354312A1
- Status: Published application
- Kind: A1
- Application number: 15/170,893
- Filed: 2016-06-01
- Published: 2016-12-08
- Earliest claimed: 2008-07-15
- Assignees: Nanocare Technologies, Inc.
- Applicants: Nanocare Technologies, Inc.
- Inventors: José Emilio Fehr Pereira Lopes
- Web page: https://patentgrep.com/patent/US20160354312A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 8/365: Hydroxycarboxylic acids; Ketocarboxylic acids
- A61K 8/37: Esters of carboxylic acids
- A61K 8/738: {Cyclodextrins}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/215: of carboxylic acids
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/24: Antidepressants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 19/00: Preparations for care of the skin
- A61K 2800/10: General cosmetic use
- A61K 2800/56: Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present disclosure provides compositions comprising a jasmonic acid derivative and a carrier, such as a liposome or cyclodextrin. Said compositions may be used for treating cancer.

## Claims

### Claim 1

A pharmaceutical formulation comprising an active principle selected from methyl jasmonate, jasmonic acid, 7-iso-jasmonic acid, 2,3-didehydrojasmonic acid, 3,4-didehydrojasmonic acid, 3,7-didehydrojasmonic acid, 4,5-didehydrojasmonic acid, 4,5-didehydro-7-isojasmonic acid, cucurbic acid, 6-epi-cucurbic acid, 6-epi-cucurbic acid-lactone, 12-hydroxy-jasmonic acid, 12-hydroxy-jasmonic acid-lactone, 11-hydroxy-jasmonic acid, 8-hydroxy-jasmonic acid, tuberonic acid, tuberonic acid-O-β-glucopyranoside, cucurbic acid-O-β-glucopyranoside, 5,6-didehydro-jasmonic acid, 6,7-didehydro-jasmonic acid, 7,8-didehydro-jasmonic acid and a lower alkyl ester thereof and a nanocarrier or microcarrier, wherein the active principle is included into, inside, associated with, conjugated with, and/or at the nanocarrier or microcarrier, and the nanocarrier or microcarrier comprises a liposome selected from a PEGylated liposome, poly(ethylene glycol)-600-hydroxystearate (PEG-HS), and LDE, the liposome being a unilamellar vesicle or a multilamellar vesicle, a dendrimer, linear bis poly(ethylene glycol) (PEG) polymer with branched spacers, a hyaluronan polymer, a peptide nanovesicle, a lipid nanotube, a cationic solid lipid microparticle, a gelatin nanoparticle, a polylactic glycolic acid nanoparticle, a hydrogel microparticle, chitosan, or a lipoglycoprotein, and further wherein the pharmaceutical formulation is in the form of an emulsion.

### Claim 2 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the active principle has a concentration of no greater than 1 M.

### Claim 3 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the active principle and the liposome form an inclusion complex.

### Claim 4 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the active principle is methyl jasmonate or jasmonic acid.

### Claim 5 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the nanocarrier or microcarrier is biodegradable.

### Claim 6 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the nanocarrier or microcarrier comprises linear bis poly(ethylene glycol) (PEG) polymer with branched spacers, a hyaluronan polymer, a peptide nanovesicle, a lipid nanotube, a cationic solid lipid microparticle, a gelatin nanoparticle, a polylactic glycolic acid nanoparticle, a hydrogel microparticle, chitosan, a lipoglycoprotein,

### Claim 7 (depends on 1)

A method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical formulation of claim 1.

### Claim 8 (depends on 1)

A method for treating a virus, bacterial, or fungal disease, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical formulation of claim 1.

### Claim 9 (depends on 1)

A method for treating an inflammatory disease, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical formulation of claim 1.

### Claim 10 (depends on 1)

A method for treating an autoimmune disease, dystrophies, or depression, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical formulation of claim 1.

### Claim 11

A cosmetic formulation comprising an active principle selected from methyl jasmonate, jasmonic acid, 7-iso-jasmonic acid, 2,3-didehydrojasmonic acid, 3,4-didehydrojasmonic acid, 3,7-didehydrojasmonic acid, 4,5-didehydrojasmonic acid, 4,5-didehydro-7-isojasmonic acid, cucurbic acid, 6-epi-cucurbic acid, 6-epi-cucurbic acid-lactone, 12-hydroxy-jasmonic acid, 12-hydroxy-jasmonic acid-lactone, 11-hydroxy-jasmonic acid, 8-hydroxy-jasmonic acid, tuberonic acid, tuberonic acid-O-β-glucopyranoside, cucurbic acid-O-β-glucopyranoside, 5,6-didehydro-jasmonic acid, 6,7-didehydro-jasmonic acid, 7,8-didehydro-jasmonic acid and a lower alkyl ester thereof, and a nanocarrier or microcarrier, wherein the active principle is included into, inside, associated with, conjugated with, and/or at the nanocarrier or microcarrier, and the nanocarrier or microcarrier comprises a liposome selected from a PEGylated liposome, poly(ethylene glycol)-600-hydroxystearate (PEG-HS), and LDE, the liposome being a unilamellar vesicle or a multilamellar vesicle, a dendrimer, linear bis poly(ethylene glycol) (PEG) polymer with branched spacers, a hyaluronan polymer, a peptide nanovesicle, a lipid nanotube, a cationic solid lipid microparticle, a gelatin nanoparticle, a polylactic glycolic acid nanoparticle, a hydrogel microparticle, or a lipoglycoprotein, and further wherein the cosmetic formulation is in the form of an emulsion.

### Claim 12 (depends on 11)

The cosmetic formulation of claim 11, wherein the active principle is methyl jasmonate or jasmonic acid.

### Claim 13 (depends on 11)

The cosmetic formulation of claim 11, wherein the nanocarrier or microcarrier comprises a dendrimer selected from polyamidoamine (PAMAM) G4 hydroxyl terminated dendrimer, Methotrexate-carrying PAMAM (PAMAM/MTX), and Methotrexate-carrying PEGylated PAMAM (PAMAM-PEG/MTX).
